Abstract:Humans exhibit substantial inter-individual differences in pain perception, which contributes to variability in analgesic efficacy. Individual differences in pain sensitivity have been linked with variation in the serotonin transporter gene (5-HTTLPR), and selective serotonin reuptake inhibitors (SSRIs) such as citalopram have been increasingly used as treatments for multiple pain conditions. We combined genotyping, pharmacological challenge, and neuroimaging during painful electrical stimulation to reveal how serotonin genetics and pharmacology interact to influence pain perception and its underlying neurobiological mechanisms. In a double-blind, placebo-controlled procedure, we acutely administrated citalopram (30mgpo) to short/short (s/s) and long/long (l/l) healthy male 5-HTTLPR homozygotes during functional MRI with painful and non-painful electrical stimulation. 5-HTTLPR genotype modulated citalopram effects on pain-related brain responses in the thalamus, cerebellum, anterior insula, midcingulate cortex and inferior frontal cortex. Specifically, citalopram significantly reduced pain-related brain responses in l/l but not in s/s homozygotes. Moreover, the interaction between 5-HTTLPR genotype and pain-related brain activity was a good predictor of the citalopram-induced reductions in pain reports. The genetic modulations of citalopram effects on brain-wide pain processing were paralleled by significant effects on the Neurological Pain Signature, a multivariate brain pattern validated to be sensitive and specific to physical pain. This work provides neurobiological mechanism by which genetic variation shapes brain responses to pain perception and treatment efficacy. These findings have important implications for the types of individuals for whom serotonergic treatments provide effective pain relief, which is critical for advancing personalized pain treatment.

Association Study of 5-HT2A Receptor Gene Polymorphism with Persistent Somatoform Pain Disorder and the Efficacy of Fluoxetine

Association Of Brain-Derived Neurotrophic Factor Genetic Val66met Polymorphism With Severity Of Depression, Efficacy Of Fluoxetine And Its Side Effects In Chinese Major Depressive Patients

Clinical study of duloxetine in treatment of persistent somatoform pain disorder

Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.

A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.

5-Htr1a And 5-Htr2a Genetic Polymorphisms And Ssri Antidepressant Response In Depressive Chinese Patients

Study on the relationship between serotonin receptor 2A gene polymorphism and clinical response to paroxetine

Cost-effectiveness analysis of fluoxetine for patients with persistent somatoform pain disorder

A study on the association between T102C polymorphism in the 5-HT2a receptor gene and responses to clozapine

[Molecular Pharmacogenetic Studies of Drug Responses to Obsessive-Compulsive Disorder and Six Functional Genes].

Association Study of Multidrug Resistance 1 Gene Polymorphisms with Efficacy and Adverse Drug Reaction of Paroxetine in Major Depressive Patients

Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

Serotonin transporter gene and antidepressant efficacy of selective serotonin reuptake inhibitors in adolescent depression

Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders.

A control study of duloxetine versus fluoxetine in the treatment of somatoform disorders

Serotonin transporter polymorphism alters citalopram effects on human pain responses to physical pain

Association Analysis of Serotonin 2A Receptor Gene Polymorphism and Obsessive-Compulsive Disorder

Clinical Characteristics and Association Analysis of Serotonin 2A Receptor Gene T102C Polymorphism with Obsessive Compulsive Symptoms in Three Different Conditions

Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients

Association between SLC17A7 gene polymorphisms and venlafaxine for major depressive disorder in a Chinese Han population: a prospective pharmacogenetic case-control study

No Association Between <i>SLC6A4</i> Gene Polymorphisms With Treatment Remission to Venlafaxine in Han Chinese Depressive Patients